Q-omics provides the consensus-scored UBE2L4 profile across patient tissues and cancer cell-line models. UBE2L4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UBE2L4 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, UBE2L4 RNA expression shows 12,887 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, HNSC, and KIRP as cancer lineages where UBE2L4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2L4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2L4 survival associations across molecular data types. UBE2L4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2L4 RNA expression–survival associations across cancer types. High UBE2L4 expression shows unfavorable associations in LIHC, but favorable associations in BLCA, DLBC, CESC, COAD and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for UBE2L4 RNA expression.
This table summarizes UBE2L4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2L4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2L4 shows higher tumor expression in HNSC, BLCA, LIHC, CHOL, COAD and LUSC. The HNSC box plot shows higher UBE2L4 RNA expression in tumor versus normal tissue (log2 FC = +0.161, t-test p = .003).
This table shows molecular features associated with UBE2L4 in patient tissues and cancer cell lines. In patient samples, UBE2L4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
